Johnson & Johnson (JNJ) Stock: Rises to $273 as FDA Approves RYBREVANT FASPRO for Head and Neck Cancer

TLDR JNJ shares gain 0.35% as FDA approval adds a new head and neck cancer treatment. RYBREVANT FASPRO targets EGFR and MET in certain advanced head and neck cancers. The FDA approval excludes HPV-associated oropharyngeal squamous cell carcinoma. OrigAMI-4 trial reports a 42% response rate across 102 previously treated patients. FDA approval expands JNJ’s oncology [...]

The post Johnson & Johnson (JNJ) Stock: Rises to $273 as FDA Approves RYBREVANT FASPRO for Head and Neck Cancer appeared first on Blockonomi.